2500 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Venus Medtech (Hangzhou), Inc. provides transcatheter heart valve medical device. It engages in the research and development of cardiac intervention system for heart diseases. The company offers pre-implanted invasive heart valve systems such as transcatheter artery and pulmonary artery valve systems, and delivery catheter systems. The company was founded on July 3, 2009 and is headquartered in Hangzhou, China.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
2500 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company